205 related articles for article (PubMed ID: 32250548)
21. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
Joshi S; Singh AR; Durden DL
Cancer Chemother Pharmacol; 2015 Mar; 75(3):595-608. PubMed ID: 25578041
[TBL] [Abstract][Full Text] [Related]
22. A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2.
Kim SY; Keillor JW
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260198
[TBL] [Abstract][Full Text] [Related]
23. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma.
Gong K; Zhang N; Zhang K; Na Y
Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786
[TBL] [Abstract][Full Text] [Related]
24. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
[TBL] [Abstract][Full Text] [Related]
25. Metformin Induces Different Responses in Clear Cell Renal Cell Carcinoma Caki Cell Lines.
Pasha M; Sivaraman SK; Frantz R; Agouni A; Munusamy S
Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30909494
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways.
Selvarajah J; Nathawat K; Moumen A; Ashcroft M; Carroll VA
Cell Death Dis; 2013 Oct; 4(10):e865. PubMed ID: 24136229
[TBL] [Abstract][Full Text] [Related]
27. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
Motzer RJ; Hutson TE; Hudes GR; Figlin RA; Martini JF; English PA; Huang X; Valota O; Williams JA
Cancer Chemother Pharmacol; 2014 Oct; 74(4):739-50. PubMed ID: 25100134
[TBL] [Abstract][Full Text] [Related]
28. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
Ji SQ; Su XL; Cheng WL; Zhang HJ; Zhao YQ; Han ZX
Urol Oncol; 2014 Feb; 32(2):153-61. PubMed ID: 23273913
[TBL] [Abstract][Full Text] [Related]
29. Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.
Kong HS; Lee S; Beebe K; Scroggins B; Gupta G; Lee MJ; Jung YJ; Trepel J; Neckers L
Mol Pharmacol; 2010 Dec; 78(6):1072-8. PubMed ID: 20813864
[TBL] [Abstract][Full Text] [Related]
30. Zafirlukast Induces VHL- and HIF-2α-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells.
Wolf C; Smith S; van Wijk SJL
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408930
[TBL] [Abstract][Full Text] [Related]
31. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
He Z; Liu S; Guo M; Mao J; Hughson MD
Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
[TBL] [Abstract][Full Text] [Related]
32. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
Shinojima T; Oya M; Takayanagi A; Mizuno R; Shimizu N; Murai M
Carcinogenesis; 2007 Mar; 28(3):529-36. PubMed ID: 16920734
[TBL] [Abstract][Full Text] [Related]
33. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma.
Lidgren A; Hedberg Y; Grankvist K; Rasmuson T; Vasko J; Ljungberg B
Clin Cancer Res; 2005 Feb; 11(3):1129-35. PubMed ID: 15709180
[TBL] [Abstract][Full Text] [Related]
34. Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression.
Di Cristofano C; Minervini A; Menicagli M; Salinitri G; Bertacca G; Pefanis G; Masieri L; Lessi F; Collecchi P; Minervini R; Carini M; Bevilacqua G; Cavazzana A
Am J Surg Pathol; 2007 Dec; 31(12):1875-81. PubMed ID: 18043042
[TBL] [Abstract][Full Text] [Related]
35. ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma.
Green YS; Ferreira Dos Santos MC; Fuja DG; Reichert EC; Campos AR; Cowman SJ; Acuña Pilarte K; Kohan J; Tripp SR; Leibold EA; Sirohi D; Agarwal N; Liu X; Koh MY
Oncogene; 2022 Oct; 41(42):4709-4723. PubMed ID: 36097192
[TBL] [Abstract][Full Text] [Related]
36. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
37. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.
Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST
PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124
[TBL] [Abstract][Full Text] [Related]
38. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
39. β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma.
Dere R; Perkins AL; Bawa-Khalfe T; Jonasch D; Walker CL
J Am Soc Nephrol; 2015 Mar; 26(3):553-64. PubMed ID: 25313256
[TBL] [Abstract][Full Text] [Related]
40. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
